ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cabozantinib

Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.

Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.

Drug pageCabozantinib: every studyMany companies study it; this page follows only the 33 they lead. All 223 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 8, 201333 company-led studies, 8 open or runningNext primary completion: Aug 25, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixis237 open or runningphase 4since Jul 8, 2013Sep 20, 2005May 31, 2030phase 3 · NCT07620574
Bristol-Myers Squibbits history only51 open or runningphase 3since May 3, 2017Nov 24, 2009Aug 25, 2029phase 2 · NCT03899155
Ipsenits history only20 open or runningphase 2since May 9, 2019May 9, 2019none ahead
Takedaits history only20 open or runningphase 2since Nov 8, 2017Nov 8, 2017none ahead
Academic Thoracic Oncology Medical Investigators Consortiumits history only10 open or runningphase 2since Apr 23, 2018Apr 23, 2018none ahead

Also a collaborator on its studies: Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Roche-Genentech and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Sep 20, 2005.

  1. Jan 13, 2012Phase 3 study in Prostatic NeoplasmsNCT01522443 · 119 enrolled · United States, Australia, Canada and more
  2. Mar 9, 2012Phase 1 study in NeoplasmsNCT01553656 · 85 enrolled · Japan
  3. May 22, 2012Phase 3 study in Prostatic NeoplasmsNCT01605227 · 1,028 enrolled · United States, Australia, Austria and more
  4. Jan 3, 2013Phase 1 study in Renal InsufficiencyNCT01761773 · 32 enrolled · United States
  5. May 21, 2013Phase 3 study in Carcinoma, Renal CellNCT01865747 · 658 enrolled · United States, Argentina, Australia and more
  6. Jul 8, 2013Phase 4 study in Carcinoma, MedullaryNCT01896479 · 247 enrolled · Australia, Canada, Croatia and more
  7. Jul 23, 2013Phase 3 study in Carcinoma, HepatocellularNCT01908426 · 707 enrolled · United States, Australia, Belgium and more
  8. Nov 14, 2013Phase 2 study in Prostatic NeoplasmsNCT01995058 · 54 enrolled · United States
  9. May 23, 2017Phase 1 study in Carcinoma, Transitional CellNCT03170960 · 914 enrolled · United States, Australia, Belgium and more
  10. Sep 26, 2018Phase 3 study in Thyroid Cancer, PapillaryNCT03690388 · 187 enrolled · United States, Argentina, Australia and more
  11. Nov 26, 2018Phase 3 study in Carcinoma, HepatocellularNCT03755791 · 837 enrolled · United States, Argentina, Australia and more
  12. May 2, 2019Phase 3 study in Carcinoma, Renal CellNCT03937219 · 855 enrolled · United States, Argentina, Australia and more
  13. Jun 22, 2020Phase 3 study in Prostatic NeoplasmsNCT04446117 · 575 enrolled · United States, Argentina, Australia and more
  14. May 27, 2026Phase 3 study in NeoplasmsNCT07620574 · 5,000 planned · United States

Ahead

  1. May 31, 2030Primary completion: phase 3 study in NeoplasmsNCT07620574

TargetBeta

KDR →MET →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
zanzalintinibruleExelixisphase 317

Studies

All 23 Exelixis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07620574Neoplasms · United States3By invitationMay 31, 20305,000
NCT04446117Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingApr 19, 2024575
NCT03937219Carcinoma, Renal Cell · United States, Argentina, Australia and more3Active, not recruitingJan 31, 2022855
NCT03755791Carcinoma, Hepatocellular · United States, Argentina, Australia and more3Active, not recruitingNov 30, 2021837
NCT03690388Thyroid Cancer, Papillary · United States, Argentina, Australia and more3Active, not recruitingAug 19, 2020187
NCT03170960Carcinoma, Transitional Cell · United States, Australia, Belgium and more1Active, not recruitingFeb 21, 2023914
NCT01995058Prostatic Neoplasms · United States2TerminatedNov 201454
NCT01908426Carcinoma, Hepatocellular · United States, Australia, Belgium and more3CompletedOct 16, 2017707
NCT01896479Carcinoma, Medullary · Australia, Canada, Croatia and more4Active, not recruitingJul 15, 2020247
NCT01865747Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedMay 22, 2015658
NCT01761773Renal Insufficiency · United States1CompletedApr 201332
NCT01605227Prostatic Neoplasms · United States, Australia, Austria and more3CompletedSep 20141,028
NCT01553656Neoplasms · Japan1CompletedMay 201585
NCT01522443Prostatic Neoplasms · United States, Australia, Canada and more3TerminatedOct 2014119
NCT01493869Healthy · United States1CompletedMay 201426
NCT01100619Thyroid Cancer, Papillary · United States1CompletedAug 201240
NCT01068782Glioblastoma · United States, Canada2TerminatedMay 201119
NCT00960492Glioblastoma · United States1CompletedNov 201226
NCT00940225Neoplasms · United States, Belgium, Israel and more2CompletedMay 2013730
NCT00704730Thyroid Neoplasms · United States, Austria, Belgium and more3CompletedOct 2011330
NCT00704288Glioblastoma · United States2CompletedJun 2012222
NCT00596648Carcinoma, Non-Small-Cell Lung · United States2CompletedAug 2, 201292
NCT00215605Lymphoma · United States1CompletedApr 201185

How it is read

Names in the registry

  • “Cabozantinib”, 18 entries
  • “cabozantinib”, 9 entries
  • “XL184”, 6 entries
  • “Cabozantinib tablets”, 2 entries
  • “Cabozantinib (XL184) 140 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.